Key Takeaways:
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) announced the termination of its business combination agreement with Nutravisor Inc., a deal that would have resulted in a reverse takeover of Entheon. The collapse of the transaction halts Entheon's previously announced plans for a share consolidation and name change.
"The definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026, has been terminated," the company said in a statement.
Following the termination, Nutravisor will provide Entheon with a settlement package totaling CAD$350,000. This includes a cash payment of CAD$175,000 and an additional CAD$175,000 in common shares of Nutravisor or its resulting issuer from a future go-public transaction. The share value will be determined based on the greater of CAD$0.50 per share or 80% of the price in Nutravisor's next liquidity event.
The termination of the reverse takeover marks a significant strategic setback for Entheon, a biotechnology company focused on addiction and substance use disorders. The deal's failure prevents the realization of expected synergies and creates uncertainty about the company's future direction. Trading in Entheon's common shares is currently halted, and the company has stated it will provide updates on the resumption of trading in due course.
This article is for informational purposes only and does not constitute investment advice.
